Enzymotec Ltd
ENZY
ENZY was delisted on the 10th of January, 2018.
22 hedge funds and large institutions have $57.1M invested in Enzymotec Ltd in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 9 reducing their positions, and 8 closing their positions.
12% less funds holding
Funds holding: 25 → 22 (-3)
33% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 9
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
47% less capital invested
Capital invested by funds: $108M → $57.1M (-$50.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.59M |
| 2 |
MACM
March Altus Capital Management
Greenwich,
Connecticut
|
+$6.63M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.6M |
| 4 |
Millennium Management
New York
|
+$670K |
| 5 |
VAM
Visium Asset Management
New York
|
+$270K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
Matterhorn Capital Management
San Antonio,
Texas
|
-$3.5M |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.83M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
-$1.51M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$804K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$703K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Alyeska Investment Group
Chicago,
Illinois
| – | -$703K | -51,840 | Closed |
|
|
BIM
27
BlackRock Investment Management
Wilmington,
Delaware
| – | -$423K | -31,157 | Closed |
|
28
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$145K | -10,759 | Closed |
|
29
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$102K | -7,513 | Closed |
|
|
U
30
UBS
Zurich,
Switzerland
| – | -$4K | -281 | Closed |
|
ENZY Hedge Fund Activity: Q3 2014 in Review
22 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Enzymotec Ltd (ENZY) for Q3 2014, worth a combined $57.1M — down 47% from $108M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ENZY and 5 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 6 added.
The largest buyer was Fidelity Investments, adding an estimated $7.59M. The largest seller was Matterhorn Capital Management, exiting entirely with an estimated $3.5M sold.
- 22 institutional investors held Enzymotec Ltd (ENZY) as of Q3 2014, down from 25 in Q2 2014.
- Funds reported $57.1M of Enzymotec Ltd stock for Q3 2014, down 47% quarter-over-quarter.
- 5 funds opened new Enzymotec Ltd positions in Q3 2014 and 8 closed out, a net change of -3 holders.
- The largest Enzymotec Ltd buyer in Q3 2014 was Fidelity Investments, an estimated $7.59M added.
- The largest Enzymotec Ltd seller in Q3 2014 was Matterhorn Capital Management, an estimated $3.5M sold.
Based on aggregated 13F filings for Q3 2014.